Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Didanosine; Factor VIII; Indinavir; Lamivudine; Stavudine; Zalcitabine; Zidovudine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are an HIV-positive male.

• Have been diagnosed with hemophilia.

• Have been taking clotting factors for hemophilia for at least 6 months.

• Have been taking a combination of one protease inhibitor plus two other anti-HIV drugs for at least 6 months, or have never taken a protease inhibitor.

• Are at least 16 years old (consent of parent or guardian required if under 18).